butabarbital decreases outcomes of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may well minimize sufentanil levels and efficacy, potentially precipitating withdrawal syndrome in people that have designed Bodily dependence to sufentanil. Discontinuation